CADISS: a feasibility trial that answered its question
Anticoagulation after ischaemic stroke was a topic of major controversy for decades until a series of randomised clinical trials consistently showed no net benefi t of heparin or warfarin compared with aspirin. 1, 2 Any reduction in the risk of recurrent ischaemic stroke was off set by an increase in risk of intracerebral haemorrhages. One cause of stroke for which the eff ect of anticoagulation remains unclear is cervical artery dissection. The classic dogma was that a tear in the intima leads to formation of a fi brin-rich thrombus and poses a very high risk of artery-to-artery embolism or occlusion, making early anticoagulation the treatment of choice. 3 Furthermore, this risk was thought to persist for months until the artery heals. Countless experts recommended this approach, but acknowledged the lack of dependable data.
Observational studies have yielded confl icting results. [4] [5] [6] A systematic review and meta-analysis 7 of 36 observational studies showed no signifi cant diff erences between anticoagulation and antiplatelet treatment for clinical outcomes or risk of recurrent stroke. For doctors inclined to use anticoagulation, the point estimates suggested a potential benefi t. For those who were sceptical, the neutral results provided no compelling reason to use anything other than antiplatelet treatment. American Heart Association/ American Stroke Association guidelines 8, 9 left open both options, suggesting that either approach is reasonable for 3-6 months (class IIa, level B, a weak recommendation), although these guidelines otherwise strongly recommend antiplatelet treatment over anticoagulation for acute management and secondary prevention after non-cardioembolic stroke (class I, level A, their highest endorsement).
The Cervical Artery Dissection in Stroke Study (CADISS) was the fi rst randomised clinical trial to compare anticoagulation with antiplatelet treatment for cervical artery dissection. It was designed as a pilot study, aiming to estimate the risk of recurrent stroke reliably and establish whether a defi nitive trial would be feasible. The main results, published in The Lancet Neurology, 10 are much the same as those from the other anticoagulation trials-any reduction in ischaemic stroke was counterbalanced by an increase in haemorrhages. However, events were rare, with only four ischaemic strokes (three in the antiplatelet group and one in the anticoagulant group) and one subarachnoid haemorrhage (in the anticoagulant group) among the 250 participants. The rarity of events meant that the study did not answer the question of which strategy was superior overall, but that was not expected from this pilot trial.
Nevertheless, CADISS informs both clinical practice and clinical research. First, dissection might be harder to diagnose than one might think. About 20% of dissections in this trial could not be confi rmed by central review of vascular imaging. Perhaps other factors, including age or localised pain, led to a presumptive diagnosis without defi nitive imaging data. Diagnoses need to be improved for future studies of treatment for dissection. Second, the overall risk of stroke was low, suggesting that dissection might be less of a problem than traditionally thought. The risk of stroke was zero for patients who presented with anything other than an initial stroke. Although representing only a subset of patients, this very low risk is consistent with observational data 4 and suggests that anticoagulation should not routinely be recommended in this context. Third, all stroke events occurred in the fi rst 10 days after randomisation. This would suggest that patients who present late are probably another very low risk group. Additionally, for those who still prefer anticoagulation even after reading the CADISS results, the duration of such treatment might be shortened to less than several months.
Some questions remain unanswered. Because of practical considerations, CADISS enrolled patients up to 7 days after onset of symptoms, or even longer if they presented with stroke and prodromal symptoms. Patients with very early recurrent strokes might therefore never have been enrolled, so there could be an unseen higher risk group for which data are lacking. Further, radiographic features of dissection, both at the time of diagnosis and during the healing process, might be associated with subsequent stroke risk.
The CADISS investigators estimated that a future trial with a similar design would need to enrol 10 000 participants to detect a 1% diff erence in occurrence of ipsilateral stroke or death or major bleeding between anticoagulation and antiplatelet Stroke is a leading cause of death and disability worldwide, with few eff ective acute treatments. For patients with ischaemic stroke who present promptly to a properly equipped hospital and receive intravenous alteplase within 4·5 h, chance of regaining excellent functional outcome is greatly increased.
1 The treatment eff ect decays rapidly with time, and patients with larger clot burden or more severe strokes often do not respond to alteplase. Many attempts have been made to determine whether alternative drugs or devices might be more eff ective than alteplase, but breaking up arterial clots has proven hard to do.
Pilot studies suggested that tenecteplase, which is more fi brin-specifi c and easier to deliver, might be an alternative to alteplase. 2 However, as reported in The Lancet Neurology, the ATTEST study failed to show a diff erence between tenecteplase versus alteplase when administered within 4·5 h of stroke onset. 3 52 patients were randomly assigned to alteplase and 52 to tenecteplase and were treated based on eligibility criteria for traditional intravenous alteplase and a non-contrast head CT; they subsequently underwent attempted CT perfusion imaging and CT angiography. The primary endpoint-the percentage of initial territory-at-risk on CT perfusion that did not progress to infarct on follow-up non-contrast CT-showed no signifi cant diff erences between the two drugs in degree of penumbral salvage (68% [SD 28] with tenecteplase treatment. If the population could be restricted to those who present with stroke, are correctly and rapidly diagnosed, and are then enrolled and treated early, maybe only half or even a quarter as many participants would be needed. Testing of newer oral anticoagulants, which are probably safer and easier to manage than warfarin, should also be considered. 11 Should investigators forge ahead? Despite having outstanding sites in the UK and Australia, and allowing for a generous time window, recruitment into CADISS occurred at an average of one participant per centre per year. A study of 5000 participants might require 500 sites and 10 years to complete recruitment. The primary objective of CADISS was to establish the feasibility of a defi nitive clinical trial comparing antiplatelet treatment with anticoagulation for patients with cervical artery dissection. The investigators achieved their objective-that pivotal trial is not feasible at present. Antiplatelet treatment seems to be the safer, more convenient, and less costly default treatment for now, but eff orts should continue to understand the pathophysiology of dissection and to identify and characterise the rare patients who remain at risk for subsequent stroke.
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